Lotte Holdings Makes First European Biotech Investment, Backing ClearideBio's Next-Generation ADC Pipeline
核心洞察
Japan's Lotte Holdings (搜索) has made its first investment in a European biotechnology company, leading a pre-seed financing round for Basel-based ClearideBio Therapeutics AG (搜索).
ClearideBio is a preclinical-stage startup founded in December 2025, focused on developing next-generation antibody-drug conjugates (搜索) (ADCs) for solid tumor indications.
The company is advancing its lead preclinical ADC program toward initial clinical development, with first-in-human studies anticipated in the coming years.
Japan's Lotte Holdings (搜索) has announced a strategic investment in ClearideBio Therapeutics AG (搜索), a preclinical-stage biotechnology startup based in Basel, Switzerland, marking the conglomerate's first foray into the European biotechnology sector. Lotte participated as the lead investor in ClearideBio's pre-seed financing round, signaling strong conviction in the company's scientific approach and long-term potential.
ClearideBio, founded in December 2025, is pioneering next-generation antibody-drug conjugates (搜索) (ADCs) for the treatment of solid tumors (搜索). The company is building a rapidly expanding pipeline of ADC programs designed to address critically unmet medical needs in oncology.
Pipeline and Development Strategy
ClearideBio is currently advancing its lead preclinical ADC program toward initial clinical development while continuing to expand its broader pipeline of next-generation ADC assets targeting multiple solid tumor indications. The company's near-term development strategy focuses on progressing preclinical programs through key value-inflection milestones, with the goal of entering first-in-human studies in the coming years.
The company's approach centers on developing ADCs with potentially improved therapeutic profiles compared to currently available options, though specific target antigens and payload technologies have not been publicly disclosed at this early stage.
Strategic Significance for Lotte Holdings (搜索)
This investment represents a notable expansion of Lotte Holdings (搜索)' biotechnology investment strategy beyond its established presence in Asia. Lotte Biologics Co., the drug consignment development and production unit of South Korea's Lotte Group, has been actively building its capabilities in the ADC space, with the company recently indicating it aims to secure its first ADC CDMO order in 2025.
By backing ClearideBio at the pre-seed stage, Lotte Holdings (搜索) is positioning itself to support innovative ADC technology development from the earliest phases, potentially creating synergies with its broader biopharmaceutical manufacturing ambitions.
ADC Market Context
The ADC field has attracted substantial investment and partnership activity in recent years, with multiple approved therapies and a robust clinical pipeline across the industry. ClearideBio's emergence adds to a growing ecosystem of next-generation ADC companies seeking to improve upon first-generation technologies through novel linker chemistries, payload innovations, and targeting strategies.
The company's preclinical status means significant development work remains before clinical proof-of-concept can be established. As with all early-stage biotechnology investments, the path from preclinical research to clinical validation carries inherent scientific and regulatory risks.